Clinical Trial

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 21, 2023 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of human BCMA targeted CAR-NK Cells injection, and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory multiple myeloma or plasma cell leukemia.
Trial Details
NCT Number NCT06045091
Lead Sponsor Hrain Biotechnology Co., Ltd.
Collaborators: Shanghai Changzheng Hospital
Conditions Multiple Myeloma, Plasma Cell Leukemia
Enrollment 18 participants
Start Date 2023-07-04
Primary Completion 2025-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-09-21